8-K: Connect Biopharma raises $20.2M, posts positive data

Connect Biopharma secured a $20.2 million private placement and reported encouraging IV rademikibart Phase 1 asthma/COPD data alongside strong 52-week Phase 3 atopic dermatitis results from partner Simcere.

Summary

• On March 29, 2026, Connect Biopharma entered a securities purchase agreement for a private placement of 6,130,000 ordinary shares at $3.25 per share (for purchasers not owned/controlled by a company insider), for expected gross proceeds of approximately $20.2 million; closing is expected March 31, 2026, subject to customary conditions.
• Net proceeds together with existing cash, cash equivalents, and short‑term investments are expected to fund operations into the second half of 2027.
• A resale registration statement for the new shares will be filed within 45 days after closing and kept effective until all shares are sold or eligible for unrestricted resale under Rule 144; failure to meet filing/effectiveness timelines can trigger liquidated damages of 1.0% per 30 days (capped at 5.0%).
• Phase 1 (CBP‑201‑105) IV rademikibart: a single 300 mg 2‑minute IV push in asthma and COPD showed rapid FEV1 improvement (many patients 100–>400 mL by 15 minutes; mean ~200–400 mL) maintained through Day 29; no serious or severe AEs and no discontinuations.
• Part B of the Phase 1 study randomized adult patients with stable asthma (n=12) and COPD (n=10) 4:1 to 300 mg IV rademikibart or placebo; mean baseline FEV1 was 1.9 L (asthma) and 1.55 L (COPD); the majority were current smokers.
• Two Phase 2 Seabreeze STAT studies in acute exacerbations of asthma and COPD are enrolling, with topline data expected in mid‑2026; Connect plans to meet the FDA to align on a Phase 3 program.
• Simcere’s Phase 3 RADIANT‑AD 52‑week study (China) in 259 moderate‑to‑severe AD patients showed at Week 52: EASI75 in 96.6%, IGA 0/1 with ≥2‑point reduction in 87.1%, and EASI90 in 85.3%; safety at 16 weeks was comparable to placebo with low conjunctivitis rates.
• Simcere has a pending NDA for rademikibart in China; under the Greater China license, Connect remains eligible for up to approximately $110 million in future milestones and tiered royalties up to low double‑digit percentages.
• Leerink Partners LLC and Cantor Fitzgerald & Co. are joint placement agents; the private placement was led by Panacea Venture with participation from other existing and new U.S. healthcare investors.
• Directors and Section 16 officers entered 45‑day lock‑up agreements effective March 29, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views the combined clinical momentum (rapid bronchodilation signal and strong AD durability) and extended runway as favorable, partially offset by dilution and the early‑stage nature of the IV results.

Positives

• Financing: approximately $20.2 million gross proceeds extend cash runway into the second half of 2027.
• Clinical catalyst: IV rademikibart produced rapid bronchodilator‑like effects (many patients ≥200 mL FEV1 gain by 15 minutes; mean ~200–400 mL through Day 29) with a clean safety profile in asthma and COPD.
• Dermatology durability: RADIANT‑AD 52‑week data reported high response rates (EASI75 96.6%, IGA 0/1 87.1%, EASI90 85.3%) and favorable safety including low conjunctivitis.
• Clear path: Phase 2 Seabreeze STAT toplines expected mid‑2026 and an FDA Phase 3 alignment meeting planned.
• Non‑dilutive optionality: up to ~$110 million in remaining milestones and tiered low double‑digit royalties from the Greater China partnership with Simcere.

Negatives

• Shareholder dilution from issuing 6,130,000 new ordinary shares.
• Securities are unregistered at issuance; liquidity depends on timely SEC effectiveness of the resale registration.
• Clinical readouts are preliminary/early stage (small Phase 1 cohorts; AD data generated by partner in China with Week 52 outcomes reported among induction responders); regulatory approvals remain pending.
• Contractual obligation to file/effect a resale registration with potential liquidated damages if timelines are missed (1.0% per 30‑day period, capped at 5.0%).

Risks

• Market conditions and satisfaction of customary closing conditions could affect the timing or completion of the private placement.
• Ability to fund operating plans depends on anticipated proceeds and existing cash resources.
• Clinical trials may not demonstrate safety or efficacy; expanded or additional trials may be required for regulatory approval.
• Timelines for data readouts and regulatory interactions may shift.
• Regulatory approvals are uncertain in the U.S., the People’s Republic of China, Europe and other jurisdictions; Simcere’s pending NDA in China may be delayed or not approved by the NMPA.
• Reliance on third parties for clinical trials and manufacturing may introduce operational risks.
• Protection, maintenance and enforcement of intellectual property and proprietary technologies may be challenged.
• If approved, market acceptance by physicians, patients, and payors is uncertain.
• SEC limitations under Rule 415 could restrict initial resale registration capacity, requiring additional filings (Remainder Registration Statement).
• Post‑closing filing obligations with the CSRC within three PRC working days must be met.

Future Outlook

Connect plans to close the private placement by March 31, 2026, file a resale registration within 45 days post‑closing, and deliver topline results from the ongoing Phase 2 Seabreeze STAT studies in mid‑2026, followed by an FDA meeting to align on Phase 3 for acute exacerbations; Simcere’s pending NDA for rademikibart in China remains a potential near‑term catalyst.

Management Comments

• CEO Barry Quart, Pharm.D.: A single IV dose of rademikibart rapidly improved lung function with meaningful FEV1 gains sustained up to four weeks, supporting a potential role in acute exacerbations and chronic treatment.
• CEO Barry Quart, Pharm.D.: RADIANT‑AD results suggest best‑in‑class potential in AD with rapid, durable efficacy and low conjunctivitis, supporting convenient long‑term dosing options.
• Michael Wechsler, MD (National Jewish Health): Rapid bronchodilation with IV rademikibart could benefit acute exacerbation care, addressing both airway function and underlying inflammation.
• Christopher Bunick, M.D., Ph.D. (Yale): The depth and durability of 52‑week AD responses and low conjunctivitis are encouraging and consistent with a differentiated IL‑4Rα mechanism.

Industry Context

StockSavvy.ai notes that rademikibart targets IL‑4Rα, the same receptor as Dupilumab (Sanofi/Regeneron), but the reported rapid bronchodilator‑like effect with IV dosing is unusual for biologics and could be clinically meaningful in acute exacerbations of asthma and COPD where few innovations exist; in AD, high 52‑week response rates and low conjunctivitis, if replicated globally, would be competitive versus established IL‑4/IL‑13 pathway agents.

Comparison to Industry Standards

• Atopic dermatitis: Dupilumab 52‑week studies (e.g., LIBERTY AD) typically report EASI75 rates in the ~60–80% range depending on regimen and population; RADIANT‑AD reports 96.6% EASI75, 87.1% IGA 0/1, and 85.3% EASI90 at Week 52 among induction responders in a China trial, suggesting potentially stronger durability but with different trial designs and populations.
• Asthma/COPD acute setting: Rapid FEV1 gains of ~200–400 mL within minutes are more characteristic of inhaled bronchodilators; a biologic (IV rademikibart 300 mg) showing bronchodilator‑like effects as early as 15 minutes is atypical and, if validated in Phase 2/3, could differentiate versus existing anti‑IL‑4/13 agents.
• Safety: Conjunctivitis is a known class effect for IL‑4/13 pathway inhibitors; the AD data here report rates not differentiated from placebo at 16 weeks and remaining low through 52 weeks, which compares favorably to published dupilumab experience.
• Capital markets: A $20.2M Reg D PIPE with resale registration within 45 days is consistent with small‑cap biotech financing norms; obligations for timely SEC registration and potential Rule 415 limits mirror standard investor protections seen in comparable PIPEs.

Corporate Governance

Stakeholder Impact

• Shareholders: Dilution from 6.13 million new shares; potential upside from clinical catalysts and extended cash runway.
• Employees: Added funding supports ongoing R&D programs and organizational stability into H2 2027.
• Patients: Early evidence of rapid bronchodilation in asthma/COPD and durable AD control could expand future treatment options if approved.
• Partners/Creditors: Clear financing plan and registration obligations reduce near‑term liquidity risk; Simcere partnership provides potential non‑dilutive cash events.

Next Steps

• Close the private placement on or about March 31, 2026, subject to customary conditions.
• File the SEC resale registration statement within 45 days after closing and work to obtain effectiveness within the agreed timelines.
• Complete required CSRC filing within three PRC working days after the Closing Date.
• Deliver topline data for the Phase 2 Seabreeze STAT asthma and COPD exacerbation studies in mid‑2026.
• Meet with the FDA to align on a Phase 3 program for acute exacerbations.
• Support Simcere’s pending NDA process for rademikibart in China.

Key Dates

Recommendation

The raise extends runway and the clinical signals are encouraging, but results remain early (small Phase 1 cohorts; partner‑run AD study in China) and regulatory risk is material; a balanced stance is warranted pending mid‑2026 Phase 2 readouts and clarity on the Phase 3 path.

Keywords

rademikibart, Connect Biopharma, CNTB, private placement, Regulation D, IL‑4R, asthma, COPD, acute exacerbations, FEV1, atopic dermatitis, RADIANT‑AD, EASI75, IGA 0/1, Simcere, NMPA, FDA, Seabreeze STAT, PIPE financing, Nasdaq